PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 3, 2026SHILAP Revista de lepidopterología1 citationsOpen Access

Dual targeting of CD155 augments the antitumor efficacy of ROR1-CAR-T cells in ovarian cancer

YYYingjun YeTLTingwei LiuCCChao Cheng

Key Points

  • Enhanced tumoricidal activity observed with bispecific CAR-T targeting CD155 and ROR1, indicating better efficacy.
  • Durable effects highlight the potential of dual-targeted therapies for improved outcomes in ovarian cancer.
  • Analysis involved a bispecific CAR-T approach focused on dual targeting, demonstrating elevated therapeutic potential.
  • Findings suggest that targeting CD155 may enable more effective strategies against ovarian cancer tumors.

Abstract

CD155 emerges as a promising therapeutic target for CAR-T therapy in OC. The bispecific CAR-T construct that co-targets CD155 and ROR1 demonstrates superior and durable tumoricidal activity, offering new perspectives on OC targeted therapy.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ye et al. (2026) studied this question.

synapsesocial.com/papers/69a75a7fc6e9836116a205f8https://doi.org/10.1007/s00262-025-04283-x
Ask AI
Helpful
Bookmark
Share
View Full Paper